Rapid Eye Movement Sleep Behavior Disorder: Management and Prognostic Counseling.
Study Goal
The researchers aimed to evaluate the effectiveness of melatonin in managing symptoms of rapid eye movement sleep behavior disorder (RBD), including reducing injurious behaviors and improving sleep quality.
Results Summary
The study suggests melatonin is effective in reducing RBD symptoms, such as dream-enactment behaviors and sleep disruption, and is recommended for most patients alongside other medications.
Population
Patients with rapid eye movement sleep behavior disorder (RBD).
Effective Dosage
Not specified
Duration
Not specified
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
melatonin | decrease | RBD symptoms | most patients | - | reduce | #1 |
clonazepam | decrease | RBD symptoms | most patients | - | reduce | #2 |
pramipexole | decrease | RBD symptoms | most patients | - | reduce | #3 |
rivastigmine | decrease | RBD symptoms | most patients | - | reduce | #4 |
Management of rapid eye movement sleep behavior disorder (RBD) includes reducing injurious dream-enactment behaviors, risk of injury to self and bedpartner, and vivid or disruptive dreams and improving sleep quality and bedpartner sleep disruption. Safety precautions should be reviewed at each visit. Medications to reduce RBD symptoms such as melatonin, clonazepam, pramipexole, and rivastigmine should be considered for most patients. Isolated RBD confers a high lifetime risk of neurodegenerative diseases with a latency often spanning many years. A patient-centered shared decision-making approach to risk disclosure is recommended. Knowledge of the risk allows for life planning and participation in research.